Anthropic purchases the biotech AI startup Coefficient Bio for $400 million.

      Anthropic has acquired Coefficient Bio, a stealth biotech AI startup established just eight months ago, in an all-stock transaction valued at over $400 million. This acquisition brings a small team of fewer than 10 individuals, mostly former computational biology researchers from Genentech, into Anthropic’s healthcare and life sciences division. It indicates a commitment beyond merely acquiring talent: Anthropic is investing significant resources in the belief that general-purpose AI can expedite drug discovery.

      First reported by The Information on Thursday, the deal values a company that had no publicly known product, disclosed revenue, or traditional traction indicators. However, it did possess a founding team with exceptional qualifications. Co-founders Samuel Stanton and Nathan C. Frey both previously worked at Prescient Design, Genentech’s computational drug discovery unit, where Frey led a multidisciplinary team focusing on biological foundation models and innovative machine learning techniques for biomolecule design. Frey has authored over 20 papers in respected journals such as Science Advances and Nature Machine Intelligence, and he received an ICLR Outstanding Paper Award in 2024 for his work on generative modeling for drug candidate discovery.

      The startup aimed for nothing less than artificial superintelligence for science. In practice, Coefficient Bio developed a platform capable of using AI to create drug research and development plans, manage clinical regulatory strategies, and identify new drug candidates. It was primarily a research-intensive operation that remained in stealth mode.

      Dimension, a New York-based venture firm established in 2023 by former partners of Lux Capital and Obvious Ventures—Adam Goulburn, Zavain Dar, and Nan Li—held approximately half of Coefficient Bio. The firm focuses on ventures at the intersection of technology and life sciences and is now reporting a 38,513 percent internal rate of return on this investment. This figure reflects not so much Coefficient Bio’s commercial readiness as it does the rapid recalibration of AI valuations for early-stage scientific investments. In contrast to Anthropic’s $380 billion post-money valuation, marked during its $30 billion Series G round in February, the acquisition reflects a mere 0.1 percent dilution.

      The Coefficient Bio team will be integrated into Anthropic’s Health Care Life Sciences group, directed by Eric Kauderer-Abrams, who was hired in 2025 with a specific goal of establishing Claude as the leading AI model in biology. “We aspire for a significant share of all global life sciences activities to be powered by Claude, akin to what occurs today in coding,” Kauderer-Abrams told CNBC when Anthropic launched Claude for Life Sciences in October 2025. This platform, which connects with tools like Benchling, PubMed, and 10x Genomics, was designed to support researchers throughout the drug discovery process, from literature review and hypothesis generation to data analysis and regulatory submissions.

      The acquisition significantly enhances that initiative. While Claude for Life Sciences provides a general research assistant, the Coefficient Bio team offers specialized knowledge, particularly in protein design and biomolecule modeling, which could assist Anthropic in developing tailored tools for pharmaceutical enterprises willing to invest heavily in AI that comprehends their molecular-level workflows.

      Anthropic is entering a competitive landscape. Google DeepMind established Isomorphic Labs to pursue AI-designed drug candidates now in clinical trials, while Nvidia announced a five-year, $1 billion collaboration with Eli Lilly in January to create an AI co-innovation lab aimed at speeding up drug discovery. OpenAI is also partnering with Moderna to expedite the development of personalized cancer vaccines. The competitive rationale is straightforward: the foundation model that becomes entrenched in biopharma R&D workflows will unlock a substantial and recurring revenue stream in a market where a single approved drug can yield billions.

      The venture capital interest in AI-biology integrations reflects this perspective. Breakout Ventures closed a $114 million fund in March specifically targeting early-stage biotechs that treat AI and biology as interconnected. Dimension is reportedly raising a $700 million third fund to reinforce the same thesis. Investors believe that the rise of autonomous AI will impact life sciences as significantly as it has software engineering, and the acqui-hire nature of deals like Coefficient Bio indicates that large model builders share this view.

      For Anthropic, the strategic calculus is apparent. The company’s run-rate revenue has reached $14 billion, achieving more than tenfold annual growth for three consecutive years, with the customer base spending over $100,000 annually on Claude having increased sevenfold. However, this growth is largely concentrated in coding, enterprise search, and general productivity. Healthcare and life sciences represent a vast adjacent market where Anthropic has established a foundation with Claude for Life Sciences but has yet to achieve the deep integration necessary for generating stable, high-margin revenues.

      Investing $400 million in stock for a pre-revenue team of fewer than 10 individuals will undoubtedly raise eyebrows. The price appears less as an assessment of Coefficient Bio’s existing assets and more as a reflection of Anthropic’s belief in what can